Physician
Khurram Abbass MD INC
Khurram Abbass MD INC was paid $527K by Medicaid between Jan 2018 and Oct 2024, across 10 billing codes. Its largest line is J0717, Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) — 98% of everything it billed.
33Billing provider infoKHURRAM ABBASS MD INC
SAN JOSE, CA 95116
SAN JOSE, CA 95116
33aNPI1386199446assigned 08/18/2016
33bProvider typeRheumatology Physician
28Total paid$527K
24GClaims7,140
24DCodes billed10
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Rheumatology Physician providers in California
Rank by total paid#33 of 147
Median peer was paid$43K
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 343 | $39.38 | |
| 2019 | 750 | $46.75 | |
| 2020 | 873 | $298.55 | |
| 2021 | 1,071 | $978.44 | |
| 2022 | 1,245 | $129K | |
| 2023 | 2,349 | $260K | |
| 2024incomplete | 509 | $137K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 98% | 324 | 289 | $516K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.3% | 4,381 | 4,261 | $7K |
| 96401 | <1% | 517 | 355 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 515 | 515 | $1K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 844 | 804 | $639.67 |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 102 | 96 | $441.50 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 220 | 202 | $355.56 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 127 | 121 | $264.25 |
| 20611 | <1% | 48 | 41 | $117.35 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 62 | 58 | $27.40 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialABBASS, KHURRAM (OWNER)